Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market
Eli Lilly and Novo Nordisk both reported strong second-quarter earnings, but investors are favoring Lilly due to its dominant market share and clearer growth trajectory. While both companies raised their outlooks, Lilly's obesity and diabetes drugs are currently outperforming Novo's offerings in the U.S. market.
Why it matters
The competition between these two pharmaceutical giants is shaping a global obesity drug market projected to exceed $100 billion by the 2030s.
The diverging paths of two GLP-1 drugmakers were on full display this week.
Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly's results , sending shares higher on Wednesday, they punished Novo a day earlier — underscoring a growing divide in Wall Street's confidence in the two obesity drug leaders.
As Lilly continues to exceed expectations and widen its edge in the obesity drug space, Novo is still racing to win back market share, restore investor confidence in its pipeline and chart a clear path toward long-term growth.
"While Novo raised guidance (as expected), the pipeline and path to sustainable growth remain less clear," BMO Capital Markets analyst Evan Seigerman said in a research note on Wednesday.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in